Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

Mansoor Raza Mirza,Elisabeth Åvall-Lundqvist,Michael J. Birrer,René dePont Christensen,Gitte-Bettina Nyvang,Susanne Malander,Maarit Anttila,Theresa L. Werner,Bente Lund,Gabriel Lindahl,Sakari Hietanen,Ulla Peen,Maria Dimoula,Henrik Roed,Anja Ør Knudsen,Louisa Boufercha,Synnöve Staff,Anders Krog Vistisen,Line Bjørge,Johanna Mäenpää

Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

2019

5505Background: Standard treatment of platinum-sensitive recurrent ovarian cancer (PSROC) is platinum based combination chemotherapy ± bevacizumab. However, this treatment modality is hardly curati...

Keywords:

Ovarian cancer
Bevacizumab
Oncology
Pathology
Internal medicine
Medicine
Chemotherapy
combination chemotherapy
treatment modality
Standard treatment
Recurrent Ovarian Cancer
platinum sensitive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations